secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001213900-25-110385
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial reports Q3 net loss $1.8M, cash $4.6M; FDA provides Phase 3 guidance for AD04
--------------------------------------------------------------------------------

- Net loss $1.8M for Q3 2025 vs $2.2M in Q3 2024; R&D expenses down 50% YoY.
- Cash and equivalents $4.6M at Sep 30, 2025; runway into Q2 2026.
- Successful End of Phase 2 meeting with FDA; obtained guidance on Phase 3 design for AD04 (AUD).
- Analytical validation of cheek swab test with Genomind for biomarker-positive patients; FDA confirmed NSR, no IDE needed.
- Patent protection extended to at least 2045 via provisional patent update filed July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/0001213900-25-110385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/ea0265418-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-110385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer